Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 6/20 | 0.49 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.45 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.45 |
| ▸ | FAP | Q12884 | 2/20 | 0.45 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.45 |
| ▸ | FNTA | P49354 | 1/20 | 0.39 |
| ▸ | FNTB | P49356 | 1/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | TACR1 | P25103 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5941840 | 0.87 | CTSK (0.43) | DPP4DPP8DPP7FAPDPP9 | |
| SCHEMBL4228425 | 0.87 | CTSK (0.43) | DPP4DPP8DPP7FAPDPP9 | |
| SCHEMBL4228428 | 0.87 | CTSK (0.43) | DPP4DPP8DPP7FAPDPP9 | |
| SCHEMBL5941794 | 0.80 | PIK3CD (0.39) | DPP4DPP8FNTAFNTBPIK3CD | |
| SCHEMBL5941804 | 0.77 | RIPK1 (0.37) | PIK3CDCTSKSLC18A3 | |
| SCHEMBL4204858 | 0.73 | PPARD (0.34) | PIK3CDSLC18A3 | |
| SCHEMBL4204854 | 0.73 | PPARD (0.34) | PIK3CDSLC18A3 | |
| SCHEMBL4221827 | 0.72 | ELANE (0.49) | — | |
| SCHEMBL4206356 | 0.71 | CTSK (0.73) | FAPCTSK | |
| SCHEMBL5941862 | 0.71 | CTSK (0.58) | CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060100431-A1 | Biologically active compounds | AMURA THERAPEUTICS LIMITED (GB) | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100431-A1 | Biologically active compounds | SOST, CTSK, CTSS | DPP4 3448/4885DPP8 947/4885DPP7 1904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.